Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRI-0621 (tazarotene) in idiopathic pulmonary fibrosis
NCT06331624Phase 2Completed
- Sponsor
- GRI Bio, Inc.
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of GRI-0621 in idiopathic pulmonary fibrosis (IPF), sponsored by GRI Bio, Inc.. Started Apr 2024; status: completed.
02
Drugs
GRI-0621
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06331624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331624.